Biologic Factors Predicting Response to Tamoxifen in Patients Registered to SWOG-8228, Ancillary
Research committees
Publication Information Expand/Collapse
2004
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study
2002
ErbB-2 amplification, ErbB-1 expression and tamoxifen response in ER-positive metastatic breast cancer; a SWOG study
2000
Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR, and pS2 by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group study
1998
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group study.
Heat shock proteins hsp27 and hsp70: Lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer: (A Southwest Oncology Group study).
Heat shock proteins hsp27 and hsp70 are not associated with clinical resistance to tamoxifen in breast cancer: A Southwest Oncology Group study.
1997
bcl-1, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study.
ER and PGR by ligand binding assay compared with ER, PGR and PS2 by IHC in predicting response to tamoxifen in metastatic breast cancer.
1996
bcl-2, p53, and response to tamoxifen in er-positive metastatic breast cancer.